Results 171 to 180 of about 2,141 (223)
Some of the next articles are maybe not open access.
Screening and Management of PTLD
Transplantation, 2023Posttransplant lymphoproliferative disorder (PTLD) represents a heterogeneous group of lymphoproliferative diseases occurring in the setting of immunosuppression following hematopoietic stem cells transplant and solid organ transplantation. Despite its overall low incidence, PTLD is a serious complication following transplantation, with a mortality ...
Lorenzo, Zaffiri, Eileen T, Chambers
openaire +2 more sources
Das pädiatrische PTLD-Register (Ped-PTLD-Register)
Der Nephrologe, 2009Lymphoproliferative Erkrankungen (PTLD) sind seltene, doch schwere Komplikationen der immunsuppressiven Therapie nach Organtransplantation. Sie entstehen meist auf dem Boden einer gestorten Immunantwort gegenuber Epstein-Barr-Virus (EBV). Im Kindesalter werden pro Jahr in Deutschland etwa 15–20 Kinder mit PTLD diagnostiziert.
B. Maecker-Kolhoff, C. Klein
openaire +1 more source
Definitions and Pathology of PTLD
2021The post-transplant lymphoproliferative disorders (PTLDs) are a spectrum of lymphoid and plasmacytic proliferations that in about 60–80% of cases are associated with the Epstein-Barr virus (EBV). They are categorized into four major categories using the 2016 World Health Organization (WHO) classification.
Steven H. Swerdlow, Steven A. Webber
openaire +1 more source
Posttransplant Lymphoproliferative Disorders (PTLDs)
2020Posttransplant lymphoproliferative disorders (PTLDs) are lymphoid or plasmacytic proliferations that develop in solid organ, bone marrow, or stem cell allograft recipients in a setting of immunosuppression. PTLDs’ spectrum ranges from usually EBV-driven reactive lymphoid/plasmacytic proliferations to EBV+ or EBV− monoclonal lymphomas or plasmacytic ...
exaly +2 more sources
2021
No therapies for PTLD after solid organ transplantation are based on data from randomized clinical trials, but available phase II trial data help guide therapeutic decision making. Reduction or cessation of immunosuppression is performed at the time of diagnosis in almost all patients.
Ralf Ulrich Trappe, Steven A. Webber
openaire +1 more source
No therapies for PTLD after solid organ transplantation are based on data from randomized clinical trials, but available phase II trial data help guide therapeutic decision making. Reduction or cessation of immunosuppression is performed at the time of diagnosis in almost all patients.
Ralf Ulrich Trappe, Steven A. Webber
openaire +1 more source
PTLD after Lung Transplantation
2021The specter of post-transplant lymphoproliferative disorder (PTLD) hangs over the lung transplant population like the legendary sword of Damocles, as an ever-present danger which is even more apparent in the pediatric population. The major risk factor, of course, is primary Epstein-Barr virus infection usually transmitted via a seropositive donor into ...
Allan R. Glanville, Gary Visner
openaire +1 more source
PTLD in Intestinal Transplant Recipients
2021Post-transplant lymphoproliferative disorder (PTLD), a lethal disease, is a direct consequence of modulation of recipient’s immune system by immunosuppression. Intestinal transplant recipients are at particular risk given the intensity of necessary immunosuppression and the volume of transplanted lymphoid tissue.
Ajai Khanna, George V. Mazariegos
openaire +1 more source
PTLD After Heart Transplantation
2021PTLD in adult and childhood heart transplant recipients remains poorly understood but is associated with double the mortality compared to recipients without PTLD. PTLD makes up the minority of malignancies (1%) in adults post-heart transplant, and, other than younger age, there is a clear paucity of data in the literature regarding risk factors for ...
Anne I. Dipchand, Michael McDonald
openaire +1 more source
Leukemia & Lymphoma, 2020
Classic Hodgkin lymphoma (CHL) is the rarest post-transplant lymphoproliferative disorder (PTLD) subtype. Few cases of patients with metachronous discordant PTLD episodes including CHL-PTLD have been reported, but the incidence of and risk factors for this phenomenon are unknown.
Ryan J. Stubbins +6 more
openaire +2 more sources
Classic Hodgkin lymphoma (CHL) is the rarest post-transplant lymphoproliferative disorder (PTLD) subtype. Few cases of patients with metachronous discordant PTLD episodes including CHL-PTLD have been reported, but the incidence of and risk factors for this phenomenon are unknown.
Ryan J. Stubbins +6 more
openaire +2 more sources
Biomarkers for PTLD diagnosis and therapies
Pediatric Nephrology, 2019Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of lymphoproliferative disorders and is a serious complication of pediatric transplantation. The majority of PTLD are associated with Epstein Barr virus (EBV) and the characteristic EBV+ B cell lymphomas are the leading post-transplant malignancy in children.
openaire +2 more sources